Discovery of orally available 1H-pyrazolo [3, 4-d] pyrimidin-4-amine derivative as a novel BTK inhibitor
-
Published:2024-09
Issue:9
Volume:17
Page:105906
-
ISSN:1878-5352
-
Container-title:Arabian Journal of Chemistry
-
language:en
-
Short-container-title:Arabian Journal of Chemistry
Author:
ZunyuanWang ,
ShuWang ,
Chai Jiazhe,
Chi Xinglong,
Ying JiaxunORCID,
Kang Youkun,
Pan Youlu,
Zeng Shenxin,
Ma Zhen,
Wang Wenyong,
Huang Wenhai
Reference24 articles.
1. Bender AT, Gardberg A, Pereira A, Johnson T, Wu Y, Grenningloh R, Head J, Morandi F, Haselmayer P, Liu-Bujalski L (2017) Ability of Bruton’s Tyrosine Kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling. Mol Pharm March, 91 (3): 208-219. doi: 10.1124/mol.116.107037.
2. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective;Brullo;Int. J. Mol. Sci.,2021
3. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation;Buhimschi;Biochem.,2018
4. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia;Byrd;N. Engl. J. Med.,2016
5. Discovery of GDC-0853, a potent, selective, and non-covalent Bruton's Tyrosine Kinase inhibitor in early clinical development;Crawford;J. Med. Chem.,2018